CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,453 enrolled
Drug / intervention
Metformin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01357135
NCT01357135N/ACompleted
CompareCT.gov

Observational Study of the Treatment and Follow-up of Patients With Type II Diabetes Receiving Bitherapy With or Without Sitagliptin (Januvia®/Xelevia®).

Merck Sharp & Dohme LLC·observational·Posted May 20, 2011·Updated Jun 5, 2017

In Brief

An observational study evaluating Metformin, Sitagliptin, and 2 other interventions for Type 2 Diabetes Mellitus. Completed, enrolled 3,453 participants.

Detailed Summary

This is an observational study to compare the effectiveness of dual therapy of Type II diabetes mellitus with metformin + sitagliptin versus metformin + a sulfonylurea in routine clinical practice in France.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 20, 2011
Enrollment StartJul 15, 2009
Primary CompletionAug 31, 2013
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 15.1 years ago

Interventions

Metformindrug

Sitagliptindrug

Sulfonylureadrug

Antihyperglycemic Medicationdrug